Pyridine and pyrazine derivatives -083
The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G 1 , G 2 , G 3 , G 4 , J, Ring A, n and R 3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
1. A compound of Formula I
wherein:
W is N;
n is O
J is O;
each of G 1 , G 2 , G 3 and G 4 is CH or N provided that not more than two of G 1 , G 2 , G 3 and G 4 represent N;
Ring A is phenyl substituted by R 1 ;
R 1 is a group of the formula Q 1 -X 2 —;
wherein X 2 is a direct bond or is selected from O, SO, SO 2 , N(R 7 ), N[C(O)R 7 ], N[C(O)N(R 7 ) 2 ], N[C(O)OR 7 ], N[SO 2 —N(R 7 ) 2 ], CO, CON(R 7 ), N(R 7 )CO, SO 2 N(R 7 ), N(R 7 )SO 2 , O—SO 2 , SO 2 —O, C(R 7 ) 2 O, OC(R 7 ) 2 , C(R 7 ) 2 , C(R 7 ) 2 N(R 7 ) and N(R 7 )C(R 7 ) 2 , wherein each R 7 is independently hydrogen or (1-8C)alkyl;
and Q 1 is heterocyclyl, or heterocyclyl-(1-3C)alkyl, wherein said heterocyclyl or the heterocyclyl within the heterocyclyl-(1-3C)alkyl group is piperazinyl; and
R 3 is hydrogen;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 , wherein:
n is O
W is N;
J is O;
G 2 is N or CH and G 1 , G 3 and G 4 are CH;
Ring A is phenyl substituted by R 1 ;
R 1 is a group of the formula:
Q 1 -Q 2 -
wherein X 2 is a direct bond or CO;
and Q 1 is heterocyclyl, or heterocyclyl-(1-3C)alkyl, wherein said heterocyclyl or the heterocyclyl within the heterocyclyl-(1-3C)alkyl group is piperazinyl; and
R 3 is hydrogen;
or a pharmaceutically acceptable salt thereof.
3. A compound of Formula I according to claim 2 which is:
3-(1,3-benzoxazol-2-yl)-5 43-(4-methylpiperazin-1-yl)phenyl]pyrazin-2-amine;
3-(1,3-benzoxazol-2-yl)-5-(4-piperazin-1-ylphenyl)pyrazin-2-amine; or
3-(1,3-benzoxazol-2-yl)-5-(3-piperazin-1-ylphenyl)pyrazin-2-amine;
or a pharmaceutically acceptable salt of a foregoing compound.
4. A pharmaceutical composition, which comprises a compound of Formula I, or a pharmaceutically acceptable salt thereof, according to claim 1 in association with a pharmaceutically acceptable diluent or carrier.